Eiger BioPharmaceuticals has reported that the Data Safety Monitoring Board (DSMB) recommended continuing subject enrolment in the Peginterferon Lambda arm of the Phase III TOGETHER platform clinical trial in Covid-19 outpatients.
Hoffmann-La Roche`s Pegasys (peginterferon alfa 2a) Receives Supplemental Approval in US
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for peginterferon lambda (Lambda) for the treatment of hepatitis delta virus (HDV) infection.
Ascletis Pharma Inc., an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, has announced the opening of its Clinical Development Shanghai Center, signalling the further expansion of R&D capability, especially in Oncology and Non-alcoholic steatohepatitis (NASH).